FDA Inspection 1293740 — Cadila Pharmaceuticals Limited
The FDA completed an inspection of Cadila Pharmaceuticals Limited on Sep 26, 2025 in Ahmedabad. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 26, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ahmedabad (India)
Additional Details
Postmarket Adverse Drug Experience (PADE)